The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

EDUCATION

Research Projects

Project: Pathogenesis of HTLV-1 subtype-C infecting remote indigenous Australians

Purcell Group

The HTLV-1 subtype-C is endemic in remote central Australian Indigenous communities with prevalence greater than 50%. Austral-Melanesian HTLV-1c infections with a high proviral load are associated with immunopathogenic conditions, such as bronchiectasis. Sequences from 30 HTLV-1c genomes reveal significant differences in the HBZ and p12 coding-regions compared to the cosmopolitan subtype-A from Africa and Japan that’s commonly associated with leukaemia and myelopathy. This project examines p12 and HBZ expression and function during HTLV-1c replication. The role of HTLV- 1c provirus-accumulation and immune-dysfunction in diminished health outcomes for indigenous central Australians will be explored using HTLV-1c integration-site mapping and T cell receptor clonotyping. 

Contact project supervisor for further
information and application enquiries

Project Supervisor

Professor Damian Purcell

Project Co-supervisor

Dr Georges Khoury

Project availability
PhD/MPhil
Master of Biomedical Science
Honours

Purcell Group

[email protected]

3 vacancies

Themes
Host Pathogens Interactions
Immunology
Viral Infectious Diseases
Cross Cutting Disciplines
Translational and Clinical Research
Genomics
Global Health
Indigenous Health

Professor Damian Purcell’s group investigates the HIV-1 and HTLV-1 human retroviruses that cause AIDS, leukaemia and inflammatory pathogenesis respectively. We study their genetic structure and gene expression with a focus on defining the mechanisms that control viral persistence and pathogenesis. We examine the molecular interplay of viral and host factors during viral infection and the innate and adaptive immune responses to viral infection. We use these molecular insights to develop new antiviral and curative therapeutics, preventive prophylactic vaccines and passive antibody microbicides and therapeutics. Some of these patented discoveries have been commercialised and we are assisting with clinical trials.


Purcell Group Current Projects